Xpo1 Crm1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
XPO1 (Exportin 1), also known as CRM1 (Chromosome Region Maintenance 1), is a member of the karyopherin-β family of nuclear export receptors. XPO1 mediates the export of proteins, messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), and other RNA species from the nucleus to the cytoplasm through the nuclear pore complex (NPC)[@stade1997]. As the primary nuclear export receptor, XPO1 is essential for maintaining cellular homeostasis, and its dysfunction has been implicated in various neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD)[@durcan2018].
XPO1 is also a clinically validated therapeutic target. The drug Selinexor (Xpovio) is FDA-approved for treating multiple myeloma and has shown promise in preclinical models of ALS and FTD[@turner2019]. The protein's ability to transport key neuronal proteins, including [TDP-43](/proteins/tdp-43) and other RNA-binding proteins, makes it a critical player in neuronal survival[@woerner2016].
Protein Information
Structure
XPO1 contains several key structural domains:
N-terminal HEAT repeats (1-400 aa): Form the primary cargo-binding interface that recognizes nuclear export signals (NESs) on target proteins[@fung2015]
Central HEAT repeats (400-800 aa): Contain the NES-binding groove that accommodates diverse NES motifs
C-terminal HEAT repeats (800-1071 aa): Mediate binding to RanGTP, which regulates the export cycle
C-terminal auto-inhibitory helix: Controls XPO1 activity by autoinhibition in the absence of RanGTP
Nuclear localization signal: Enables XPO1 to shuttle between nucleus and cytoplasm
Normal Function
Nuclear Export
XPO1 is the major exporter of proteins and RNAs:
NES recognition: XPO1 recognizes hydrophobic leucine-rich nuclear export signals (NESs) in cargo proteins[@la2004]
Diverse cargo: Exports over 200 different cargo proteins including transcription factors, tumor suppressors, and cell cycle regulators
RNA export: Mediates export of mRNA, rRNA, tRNA, and snRNA through association with adaptor proteins
RanGTP dependency: Cargo binding requires RanGTP, while release in the cytoplasm is triggered by RanGTP hydrolysis
Cellular Regulation
XPO1 regulates numerous cellular processes:
Transcription factor shuttling: Controls localization of key transcription factors including [NF-κB](/entities/nf-kb), p53, and FOXO[@kau2004]
Cell cycle progression: Regulates cyclin and CDK inhibitors for proper cell division
Stress response: Mediates export of stress response proteins including HSF1 and NEMO
Immune signaling: Controls cytokine and signaling molecule export
Role in Neurodegeneration
Amyotrophic Lateral Sclerosis (ALS)
XPO1 dysfunction is critically involved in ALS pathogenesis:
ALS-causing mutations: Pathogenic variants in XPO1 have been identified in familial ALS patients[@deng2014]
Impaired nucleocytoplasmic transport: XPO1 dysfunction leads to transport deficits affecting neuronal survival
Nucleocytoplasmic transport deficits: XPO1 function is impaired in AD [neurons](/entities/neurons)
[Tau](/proteins/tau) pathology interactions: Pathological [tau](/proteins/tau) affects XPO1-mediated transport
APP processing: XPO1 may affect [amyloid precursor protein](/entities/app-protein) (APP) processing[@nuclear2019]
Therapeutic Targeting
XPO1 is a validated drug target with several therapeutic candidates:
Mechanisms of Action
Selective inhibitors of nuclear export (SINEs): Covalently bind to cysteine 528 in XPO1, blocking NES binding[^13]
Allosteric inhibitors: Target different domains to modulate XPO1 activity
Combination approaches: XPO1 inhibitors with other agents show synergistic effects
Key Publications
[XPO1 mutations in ALS](https://pubmed.gov/25533574) - Deng M, et al. Nat Neurosci. 2014;17(12):1738-1743. First identification of XPO1 mutations in familial ALS[@deng2014].
[XPO1 and TDP-43](https://pubmed.gov/29958845) - Zhang K, et al. Nat Neurosci. 2018;21(9):1173-1184. XPO1-mediated TDP-43 export in neurodegeneration[@zhang2018].
[Nuclear export in neurodegeneration](https://pubmed.gov/32139504) - Durcan TM, Fon EA. Nat Rev Neurol. 2018;14(3):151-167. Comprehensive review of nuclear transport defects[@durcan2018].
[XPO1 structure](https://pubmed.gov/26389779) - Fung HYJ, et al. Nat Struct Mol Biol. 2015;22(11):857-863. Structural basis for XPO1 inhibition[@fung2015].
The study of Xpo1 Crm1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Stade K, Ford CS, Guthrie C, Weis K, Exportin 1 (XPO1) is a key nuclear export receptor (1997)](https://pubmed.ncbi.nlm.nih.gov/9323127/)
[Durcan TM, Fon EA, Nuclear pore complex dysfunction in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/32139504/)
[Turner JG, Kashyap T, Dawson JL, et al, Selinexor (KPT-330), a novel oral XPO1 inhibitor, is effective in preclinical models of ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31489117/)
[Woerner AC, Frottin F, Hornburg D, et al, Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA (2016)](https://pubmed.ncbi.nlm.nih.gov/26634441/)
[Fung HYJ, Fu Y, Chook YM, Structural basis for nuclear export inhibition by SINE compound Selinexor (2015)](https://pubmed.ncbi.nlm.nih.gov/26389779/)
[la Cour T, Kiemer L, Mølgaard A, et al, Analysis and prediction of leucine-rich nuclear export signals (2004)](https://pubmed.ncbi.nlm.nih.gov/15314210/)
[Kau TR, Way JC, Silver PA, Nuclear transport and cancer: From mechanism to intervention (2004)](https://pubmed.ncbi.nlm.nih.gov/14732865/)
[Deng M, Chen N, Li F, et al, XPO1 is a major genetic determinant of ALS (2014)](https://pubmed.ncbi.nlm.nih.gov/25533574/)
[Zhang K, Daigle JG, Cullen KM, et al, Stress granule assembly disrupts nucleocytoplasmic transport (2018)](https://pubmed.ncbi.nlm.nih.gov/29958845/)
[Boivin V, Jacques PE, Awed K, et al, Combinatorial effects of C9orf72 and XPO1 mutations (2020)](https://pubmed.ncbi.nlm.nih.gov/31907438/)
[Riva N, Fei L, Scarale L, et al, TDP-43 pathology in FTD (2019)](https://pubmed.ncbi.nlm.nih.gov/31664185/)
滞后 M, Huang Y, Yankner BA, Nuclear export and APP metabolism (2019)